GO:1990757 ubiquitin ligase activator activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1990757 (ubiquitin ligase activator activity) is a molecular function defined as binding to and increasing the activity of a ubiquitin ligase.
• Activators can act by promoting E3-substrate recognition, stabilizing the E3 complex, or inducing conformational changes that enhance catalysis.
• The term includes the synonym mitotic anaphase-promoting complex activator activity, reflecting its role in cell cycle regulation.
• Dysregulation of ubiquitin ligase activator activity is implicated in cancer, neurodegeneration, and developmental disorders [3,7].
• Key experimental approaches include activity-based E3 profiling, proteasome-associated ligase assays, and CRISPR-based knockout or knock-in models [5,6].
• EDITGENE provides CRISPR services to dissect activator-E3 interactions, including knockout, point mutation, knock-in, overexpression, and library screening.
Description
Ubiquitin ligase activator activity (GO:1990757) is a molecular function that describes proteins which bind to and enhance the catalytic activity of a ubiquitin ligase (E3). This activity is essential for the precise regulation of ubiquitination, a post-translational modification that controls protein stability, localization, and interactions. By modulating E3 ligases, activators can influence a wide range of cellular processes, from cell cycle progression to immune signaling [1,2]. Understanding this activity is critical for researchers studying protein degradation pathways and developing therapeutics that target ubiquitin-dependent processes [3,7]. The term is particularly relevant in cancer biology, where aberrant ubiquitination drives oncogenesis, and in neuroscience, where impaired degradation contributes to neurodegeneration [3,7].
ubiquitin ligase activator activity At A Glance
| GO ID | GO:1990757 |
|---|---|
| GO term | ubiquitin ligase activator activity |
| Ontology | molecular_function |
| Synonym | mitotic anaphase-promoting complex activator activity |
| Definition | Binds to and increases the activity of a ubiquitin ligase. |
| Major function | Enhances E3 ubiquitin ligase-mediated ubiquitination of substrate proteins. |
| Related processes | Cell cycle regulation, protein degradation, signal transduction. |
| Example activators | APC/C coactivators (Cdc20, Cdh1), other E3-binding proteins. |
| Research relevance | Targets for cancer therapy, neurodegeneration, and developmental disorders. |
What Is GO:1990757?
According to the Gene Ontology, GO:1990757 (ubiquitin ligase activator activity) is defined as the molecular function of binding to and increasing the activity of a ubiquitin ligase. This means the activator protein physically interacts with an E3 ligase and enhances its ability to transfer ubiquitin to substrate proteins. The synonym 'mitotic anaphase-promoting complex activator activity' highlights its role in activating the anaphase-promoting complex (APC/C) during mitosis.
Why Is ubiquitin ligase activator activity Important in Cell Biology?
Ubiquitin ligase activator activity is crucial because it provides a layer of regulation for ubiquitination, ensuring that E3 ligases are activated only when and where needed. This spatiotemporal control is vital for processes such as cell division, DNA repair, and immune responses [1,2]. Dysregulation of activators can lead to uncontrolled degradation of tumor suppressors or accumulation of toxic proteins, contributing to diseases like cancer and neurodegeneration [3,7]. Therefore, understanding activator mechanisms offers opportunities for therapeutic intervention, such as designing small molecules that modulate activator-E3 interactions.
• Regulates cell cycle progression by activating the anaphase-promoting complex (APC/C).
• Controls protein degradation in response to cellular stress and DNA damage.
• Modulates immune signaling by activating E3 ligases that target NF-κB pathway components.
• Implicated in cancer: aberrant activation can promote oncogenesis by degrading tumor suppressors [3,7].
• Linked to neurodegeneration: impaired activation may lead to toxic protein aggregation.
• Provides targets for drug discovery: small molecules can modulate activator-E3 interactions.
• Essential for developmental processes, including neurogenesis and organogenesis.
• Studied using activity-based profiling to identify novel activators.
• Can be hijacked by pathogens to manipulate host ubiquitination.
• Offers a means to engineer synthetic ubiquitin ligases for research and therapy.
Mechanism, Genes and Research Methods
What Happens During ubiquitin ligase activator activity?
In simple terms: An activator protein binds to an E3 ligase and switches it on, helping it attach ubiquitin to target proteins.
The process begins when an activator protein recognizes and binds to a specific E3 ubiquitin ligase. This binding event induces a conformational change in the E3 ligase, enhancing its ability to recruit ubiquitin-conjugating enzymes (E2s) and substrate proteins. The activated E3 then catalyzes the transfer of ubiquitin from the E2 to the substrate, often forming polyubiquitin chains that signal for proteasomal degradation. Activators can also promote the assembly of multi-subunit E3 complexes, such as the anaphase-promoting complex (APC/C), by facilitating the incorporation of coactivators like Cdc20 or Cdh1.
Structural Basis of Activator-E3 Interaction
In simple terms: The activator fits into a specific pocket on the E3 ligase, like a key in a lock, to turn it on.
Structural studies have revealed that activators often interact with the E3 ligase through conserved domains, such as the RING or HECT domains. For example, the APC/C coactivator Cdc20 binds to the APC/C through a conserved C-box motif, inducing conformational changes that align the catalytic site for ubiquitin transfer. Similarly, other activators may use WD40 repeats or leucine-rich regions to engage E3 ligases. These interactions are highly specific, ensuring that only the correct E3 is activated at the right time.
Regulation of Activator Activity
In simple terms: Activators themselves can be turned on or off by modifications like phosphorylation, so the process is tightly controlled.
Activator activity is regulated by post-translational modifications, including phosphorylation, ubiquitination, and sumoylation. For instance, the APC/C coactivator Cdh1 is inhibited by phosphorylation during interphase, preventing premature degradation of mitotic substrates. Additionally, activator levels can be controlled by transcription or degradation, ensuring that activation is transient and reversible. This multilayered regulation is essential for maintaining cellular homeostasis and responding to signals.
Substrate Recognition and Catalysis
In simple terms: Once activated, the E3 ligase tags specific proteins with ubiquitin, marking them for destruction or other functions.
Activated E3 ligases recognize substrates through degrons, short sequence motifs that are often exposed after post-translational modifications. The activator can enhance substrate recognition by stabilizing the E3-substrate complex or by promoting the correct orientation of the substrate for ubiquitin transfer. Catalysis involves the formation of an isopeptide bond between the C-terminal glycine of ubiquitin and a lysine residue on the substrate. This process can be processive, leading to polyubiquitin chains that dictate the fate of the substrate.
Key Genes Involved in GO:1990757 ubiquitin ligase activator activity
The following genes encode proteins that either exhibit ubiquitin ligase activator activity or are key components of the ubiquitin-proteasome system that interact with such activators.
| Gene | Major Role | Research Relevance |
|---|---|---|
| CDC20 | Activates APC/C during mitosis | Cell cycle regulation; cancer target |
| CDH1 (FZR1) | Activates APC/C in late mitosis and G1 | Tumor suppressor; neurodegeneration |
| ANAPC1 | Core subunit of APC/C | Mutations linked to developmental disorders |
| ANAPC2 | Core subunit of APC/C | Required for APC/C assembly |
| ANAPC4 | Core subunit of APC/C | Essential for mitosis |
| ANAPC5 | Core subunit of APC/C | Scaffold for coactivator binding |
| ANAPC7 | Core subunit of APC/C | Regulates APC/C activity |
| ANAPC10 | Core subunit of APC/C | Contains catalytic RING domain |
| ANAPC11 | Core subunit of APC/C | RING finger subunit |
| UBE2C | E2 conjugating enzyme | Works with APC/C |
| UBE2D1 | E2 conjugating enzyme | Interacts with various E3s |
| NEDD8 | Ubiquitin-like modifier | Activates cullin-RING ligases |
| CUL1 | Scaffold of SCF complex | Activator of SCF E3 |
| RBX1 | RING subunit of SCF | Essential for SCF activity |
| SKP1 | Adaptor of SCF | Links substrate receptors to CUL1 |
| KEAP1 | Substrate adaptor of CRL3 | Cancer and oxidative stress |
| ABLIM1 | E3 ligase | Promotes colorectal cancer |
How Is ubiquitin ligase activator activity Regulated?
Ubiquitin ligase activator activity is regulated at multiple levels. Activator proteins can be phosphorylated, which may alter their binding affinity for E3 ligases or their subcellular localization. For example, the APC/C coactivator Cdh1 is phosphorylated by cyclin-dependent kinases, preventing its association with APC/C until late mitosis. Additionally, activators can be targeted for degradation by other E3 ligases, creating feedback loops. The availability of substrates and E2 enzymes also influences activator function. Furthermore, neddylation of cullin-RING ligases is a key regulatory mechanism that activates these E3s, and is reversed by the COP9 signalosome.
ubiquitin ligase activator activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| CDC20 | Colorectal cancer, chromosomal instability | Knockout in HCT116 cells |
| CDH1 | Alzheimer's disease, neurodegeneration | Knock-in of mutant CDH1 in iPSC-derived neurons |
| ABLIM1 | Colorectal cancer metastasis | Overexpression in SW480 cells |
| KEAP1 | Colorectal cancer, oxidative stress | CRISPR knockout in organoids |
| ANAPC1 | Rothmund-Thomson syndrome | Patient-derived fibroblasts |
Cancer
Dysregulation of ubiquitin ligase activator activity is frequently observed in cancer. For instance, overexpression of the APC/C coactivator Cdc20 leads to premature degradation of securin and cyclin B, causing chromosomal instability and tumor progression. Similarly, the E3 ligase ABLIM1 promotes colorectal cancer growth and metastasis by targeting IκBα for ubiquitination and activating NF-κB signaling. Targeting activator-E3 interactions is a promising therapeutic strategy [3,7].
Neurodegeneration
Impaired ubiquitin ligase activator activity can contribute to neurodegeneration by allowing toxic proteins to accumulate. For example, mutations in the APC/C coactivator Cdh1 have been linked to Alzheimer's disease, where reduced activity leads to aberrant cell cycle re-entry and neuronal death. Additionally, dysfunction of the ubiquitin-proteasome system is a hallmark of Parkinson's disease and amyotrophic lateral sclerosis.
Developmental Disorders
Mutations in genes encoding APC/C subunits or coactivators can cause developmental disorders. For example, mutations in ANAPC1 are associated with Rothmund-Thomson syndrome, characterized by growth defects and cancer predisposition. These findings highlight the importance of precise regulation of ubiquitin ligase activator activity during development.
From ubiquitin ligase activator activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does knockout of CDC20 affect cell cycle progression? | CRISPR knockout in HeLa cells |
| Does a point mutation in CDH1 alter APC/C activation? | CRISPR point mutation in HCT116 cells |
| Can knock-in of tagged CDC20 reveal its interactome? | CRISPR knock-in of HA-tag in HEK293T cells |
| Does overexpression of ABLIM1 promote tumor growth? | Xenograft mouse model with overexpression |
| What is the role of KEAP1 activator activity in cancer? | CRISPR knockout in colorectal cancer organoids |
| Can small molecules modulate activator-E3 interaction? | Activity-based profiling in cell lysates |
How to Study the ubiquitin ligase activator activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Activity-based E3 profiling | E3 ligase activity in lysates | Identifying novel activators |
| Proteasome-associated ligase assay | Ubiquitination by proteasome-bound E3s | Studying degradation pathways |
| CRISPR knockout screen | Loss-of-function effects on activator activity | Discovering regulatory genes |
| CRISPR activation screen | Gain-of-function effects | Identifying activators |
| Cryo-EM | 3D structure of activator-E3 complex | Understanding conformational changes |
| X-ray crystallography | Atomic structure of domains | Mapping interaction interfaces |
| Ubiquitination assay | Substrate ubiquitination | Measuring E3 activity in vitro |
| Mass spectrometry | Protein interactions and modifications | Proteomic analysis of activator complexes |
Activity-Based E3 Ligase Profiling
This method uses chemical probes that covalently label active E3 ligases, allowing researchers to monitor their activity in complex lysates. It can identify novel activators and assess the impact of mutations on E3 activity.
Proteasome-Associated Ubiquitin Ligase Assays
These assays measure the ubiquitination activity of E3 ligases associated with the proteasome, providing insights into degradation pathways. They are useful for studying activators that function in the context of the proteasome.
CRISPR Screening
Genome-wide CRISPR knockout or activation screens can identify genes that regulate ubiquitin ligase activator activity. For example, a screen for modifiers of APC/C activity could reveal new activators.
Structural Biology
X-ray crystallography and cryo-EM have elucidated the structures of activator-E3 complexes, revealing how binding induces conformational changes. These studies are essential for understanding the molecular basis of activation.
How CRISPR Can Be Used to Study GO:1990757 ubiquitin ligase activator activity
Knockout
CRISPR knockout of genes encoding activators or E3 ligases can reveal their essential roles in cellular processes. For example, knocking out CDC20 in cancer cells leads to mitotic arrest and apoptosis. This approach is valuable for validating targets identified in screens.
Point Mutation
Introducing specific point mutations in activator genes can dissect the functional domains required for E3 binding and activation. For instance, mutating the C-box of Cdc20 abolishes APC/C activation, providing insights into the interaction interface.
Knock-in
Knock-in of tagged versions of activators (e.g., GFP or HA) allows for real-time imaging and interactome studies. This can reveal the spatiotemporal dynamics of activator-E3 complexes.
Overexpression
Overexpression of activators can mimic disease states, such as cancer, where elevated activator levels drive oncogenesis. This approach is useful for studying gain-of-function effects and testing therapeutics.
How EDITGENE Supports ubiquitin ligase activator activity Research
Researchers studying ubiquitin ligase activator activity-related genes often need to determine whether a candidate gene is causally involved in a specific pathway or disease. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic manipulation, from knockout to knock-in, facilitating mechanistic studies and drug target validation.
Contact EDITGENE today to design your custom CRISPR model for ubiquitin ligase activator activity research.
Frequently Asked Questions About ubiquitin ligase activator activity
What is ubiquitin ligase activator activity?
It is a molecular function (GO:1990757) where a protein binds to and increases the activity of a ubiquitin ligase, enhancing ubiquitination of target proteins.
What genes are involved in ubiquitin ligase activator activity?
Key genes include CDC20 and CDH1, which encode coactivators of the anaphase-promoting complex (APC/C), as well as components of other E3 ligase complexes [1,2].
How is ubiquitin ligase activator activity regulated?
It is regulated by post-translational modifications such as phosphorylation, which control activator binding to E3 ligases and their subcellular localization.
What diseases are associated with ubiquitin ligase activator activity?
Dysregulation is linked to cancer, neurodegeneration, and developmental disorders due to aberrant protein degradation [1,3,7].
What methods are used to study ubiquitin ligase activator activity?
Common methods include activity-based E3 profiling, proteasome-associated ligase assays, CRISPR screens, and structural biology techniques [5,6].
Can CRISPR be used to study ubiquitin ligase activator activity?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of activator function in cells and animal models [1,2].
What is the synonym for GO:1990757?
The synonym is mitotic anaphase-promoting complex activator activity, reflecting its role in cell cycle regulation.
Which E3 ligase is activated by CDC20?
CDC20 activates the anaphase-promoting complex/cyclosome (APC/C) during mitosis.
How does ABLIM1 relate to ubiquitin ligase activator activity?
ABLIM1 is an E3 ligase that promotes colorectal cancer by targeting IκBα for ubiquitination, though it may also interact with activators.
What is the role of KEAP1 in ubiquitin ligase activator activity?
KEAP1 is a substrate adaptor for a cullin-RING E3 ligase; its activity can be modulated by activators, impacting cancer progression.
Conclusion
Ubiquitin ligase activator activity (GO:1990757) is a fundamental molecular function that governs the precise activation of E3 ubiquitin ligases, impacting diverse cellular processes and disease states. Understanding its mechanisms through CRISPR-based models and biochemical assays can reveal new therapeutic targets. EDITGENE's comprehensive services empower researchers to dissect this activity with precision and efficiency.
References
- 1. Toma-Fukai S et al.. 2021. Structural Diversity of Ubiquitin E3 Ligase.. Molecules 26(21) PMID: 34771091
- 2. Zheng N et al.. 2017. Ubiquitin Ligases: Structure, Function, and Regulation.. Annu Rev Biochem 86:129-157 PMID: 28375744
- 3. He Y et al.. 2024. ABLIM1, a novel ubiquitin E3 ligase, promotes growth and metastasis of colorectal cancer through targeting IĸBα ubiquitination and activating NF-ĸB signaling.. Cell Death Differ 31(2):203-216 PMID: 38228802
- 5. Pao KC et al.. 2018. Activity-based E3 ligase profiling uncovers an E3 ligase with esterification activity.. Nature 556(7701):381-385 PMID: 29643511
- 6. Wang Z et al.. 2023. Analysis of Proteasome-Associated Ubiquitin Ligase Activity.. Methods Mol Biol 2581:57-67 PMID: 36413310
- 7. Zhu F et al.. 2024. CRL3(Keap1) E3 ligase facilitates ubiquitin-mediated degradation of oncogenic SRX to suppress colorectal cancer progression.. Nat Commun 15(1):10536 PMID: 39627198
